Holen Sie sich die Stockscreener-App
7.76
2.11%
0.16
Handel nachbörslich:
7.76
Schlusskurs vom Vortag:
$7.60
Offen:
$7.62
24-Stunden-Volumen:
211.27K
Relative Volume:
0.52
Marktkapitalisierung:
$519.84M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-122.44M
KGV:
-3.4428
EPS:
-2.254
Netto-Cashflow:
$-103.79M
1W Leistung:
+6.16%
1M Leistung:
+8.38%
6M Leistung:
-11.82%
1J Leistung:
+94.00%
1-Tages-Spanne:
$7.31
$7.76
1-Wochen-Bereich:
$7.07
$7.76
52-Wochen-Spanne:
$2.65
$12.25
Engene Therapeutics Inc Stock (ENGN) Company Profile
Firmenname
Engene Therapeutics Inc
Sektor
Branche
Telefon
(514) 332-4888
Adresse
4868 RUE LEVY, SUITE 220, SAINT-LAURENT
Compare ENGN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENGN
Engene Therapeutics Inc
|
7.76 | 509.12M | 0 | -122.44M | -103.79M | -2.254 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Engene Therapeutics Inc Stock (ENGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Eingeleitet | Jefferies | Buy |
| 2025-11-11 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-02-18 | Eingeleitet | Piper Sandler | Overweight |
| 2025-02-14 | Herabstufung | UBS | Buy → Neutral |
| 2024-12-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-27 | Eingeleitet | Raymond James | Outperform |
| 2024-11-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-08-28 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-22 | Eingeleitet | Wells Fargo | Overweight |
| 2024-04-15 | Eingeleitet | Guggenheim | Buy |
| 2024-03-28 | Eingeleitet | UBS | Buy |
| 2024-03-08 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-20 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Engene Therapeutics Inc Aktie (ENGN) Neueste Nachrichten
ENGN Options Volatility — NASDAQ:ENGN - TradingView — Track All Markets
WBB Securities initiates coverage of Engene Therapeutics (ENGN) with buy recommendation - MSN
ENGN Options Chain — NASDAQ:ENGN - TradingView — Track All Markets
Engene Therapeutics Inc. Live Share Prices and Trades. ENGNW.US Live Streaming Share Prices. - London South East
ENGN Initiates Coverage On enGene Therapeutics -- Rating Set to Buy - GuruFocus
Sentiment Watch: Is enGene Holdings Inc Equity Warrant stock a value trap2026 Major Catalysts & Weekly Stock Performance Updates - baoquankhu1.vn
Published on: 2026-04-13 18:10:23 - baoquankhu1.vn
Aug Opening: Will enGene Holdings Inc stock hit new highs in YEAR2026 Support & Resistance & Risk Managed Investment Signals - baoquankhu1.vn
Revenue Check: Is enGene Holdings Inc forming bullish engulfing patterns2026 Risk Factors & High Return Trade Guides - baoquankhu1.vn
enGene Therapeutics (FRA:S0N0) Cyclically Adjusted PS Ratio : (As of Apr. 11, 2026) - GuruFocus
Total liabilities & shareholders' equities of enGene Therapeutics Inc. – FWB:S0N0 - TradingView — Track All Markets
enGene Therapeutics Inc.: Shareholders Board Members Managers and Company Profile | CA29286X1015 - marketscreener.com
S0N0: Static price chart | enGene Therapeutics Inc. | CA29286X1015 - marketscreener.com
enGene Therapeutics Inc. Changes Name and Prepares for 2027 Commercial Launch of Detalimogene Voraplasmid for High-Risk NMIBC - Minichart
enGene Therapeutics Inc.: Revenue and Earnings Analysts Forecasts Revisions | ENGN | CA29286X1015 - marketscreener.com
ENGN: Static price chart | enGene Therapeutics Inc. | CA29286X1015 - marketscreener.com
enGene Therapeutics Inc.: Target Price Consensus and Analysts Recommendations | ENGN | CA29286X1015 - marketscreener.com
enGene Therapeutics Rebrands as Company Nears Commercialization - TipRanks
Detalimogene program drives enGene (ENGN) shift to Therapeutics focus - Stock Titan
Bull Run: What analysts say about enGene Holdings Inc Equity Warrant stockFed Meeting & Free Long-Term Investment Growth Plans - baoquankhu1.vn
Chipmakers Recap: How does enGene Holdings Inc compare to its peers2026 Spike Watch & Free Verified High Yield Trade Plans - baoquankhu1.vn
ENGE HLDGNPV: Shareholders Board Members Managers and Company Profile | CA29286M1059 - marketscreener.com
Is enGene Holdings Inc benefiting from interest rate changes2026 Market Overview & Daily Entry Point Alerts - baoquankhu1.vn
ENGNW Stock Warrant Price and Chart — NASDAQ:ENGNW - TradingView — Track All Markets
Smart Money: Is enGene Holdings Inc Equity Warrant stock a value trapMarket Risk Report & Verified Momentum Stock Watchlist - baoquankhu1.vn
EnGene Holdings Inc. will Change its Name to enGene Therapeutics Inc - marketscreener.com
enGene Therapeutics Announces Name Change Ahead of Potential 2027 Approval - National Today
enGene Announces Name Change to enGene Therapeutics Inc. - PharmiWeb.com
enGene Rebrands as enGene Therapeutics Ahead of Potential 2027 Commercial Launch - TipRanks
enGene Holdings changes name to enGene Therapeutics - Investing.com
enGene announces name change to enGene Therapeutics - TipRanks
Engene Holdings IncTo Change Name To Engene Therapeutics Inc. Effective April 8, 2026 - TradingView — Track All Markets
Three new option listings and three option delistings on April 6th - TipRanks
Analysts Offer Insights on Healthcare Companies: Alterity Therapeutics (OtherPRNAF), Tarsus Pharmaceuticals (TARS) and enGene Holdings (ENGN) - The Globe and Mail
enGene Holdings Inc (ENGN) Income Statement - TradingKey
Market Leaders: What analysts say about enGene Holdings Inc Equity Warrant stockDollar Strength & High Accuracy Trade Alerts - baoquankhu1.vn
ENGNW SEC FilingsForbion European Acquisition Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Tangible book value per share of enGene Holdings Inc. – NASDAQ:ENGNW - TradingView
enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Down 25.3% in March - MarketBeat
Bull Run: Why is enGene Holdings Inc Equity Warrant stock going upQuarterly Profit Summary & Daily Entry Point Alerts - baoquankhu1.vn
Setup Watch: What are the analyst revisions for enGene Holdings IncIs FACT stock a good investment in YEARInflation Watch & Community Consensus Trade Alerts - baoquankhu1.vn
Energy Moves: Is enGene Holdings Inc Equity Warrant impacted by rising ratesMarket Sentiment Review & Precise Trade Entry Recommendations - baoquankhu1.vn
enGene Holdings Inc. (NASDAQ:ENGN) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Analysts Offer Insights on Healthcare Companies: enGene Holdings (ENGN) and Boston Scientific (BSX) - The Globe and Mail
UBS cuts Engene Holdings stock price target on trial costs - Investing.com UK
UBS cuts Engene Holdings stock price target on trial costs By Investing.com - Investing.com South Africa
Volume Recap: Can enGene Holdings Inc Equity Warrant lead its sector in growth2026 Support & Resistance & Long Hold Capital Preservation Tips - baoquankhu1.vn
Bank Watch: Is enGene Holdings Inc a stock for growth or value investors2026 Short Interest & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Sell Signal: How does enGene Holdings Inc compare to its peersQuarterly Risk Review & Verified Momentum Stock Alerts - baoquankhu1.vn
Valuation Update: What analysts say about enGene Holdings Inc Equity Warrant stock2026 Snapshot & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Bank Watch: Is enGene Holdings Inc Equity Warrants ROE strong enough2026 Sector Review & Verified Momentum Stock Alerts - baoquankhu1.vn
Finanzdaten der Engene Therapeutics Inc-Aktie (ENGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):